138 related articles for article (PubMed ID: 17483313)
1. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.
Fernández A; Sanguino A; Peng Z; Crespo A; Ozturk E; Zhang X; Wang S; Bornmann W; Lopez-Berestein G
Cancer Res; 2007 May; 67(9):4028-33. PubMed ID: 17483313
[TBL] [Abstract][Full Text] [Related]
2. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
Mahadevan D; Cooke L; Riley C; Swart R; Simons B; Della Croce K; Wisner L; Iorio M; Shakalya K; Garewal H; Nagle R; Bearss D
Oncogene; 2007 Jun; 26(27):3909-19. PubMed ID: 17325667
[TBL] [Abstract][Full Text] [Related]
3. Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
Roberts KG; Odell AF; Byrnes EM; Baleato RM; Griffith R; Lyons AB; Ashman LK
Mol Cancer Ther; 2007 Mar; 6(3):1159-66. PubMed ID: 17363509
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Guo T; Agaram NP; Wong GC; Hom G; D'Adamo D; Maki RG; Schwartz GK; Veach D; Clarkson BD; Singer S; DeMatteo RP; Besmer P; Antonescu CR
Clin Cancer Res; 2007 Aug; 13(16):4874-81. PubMed ID: 17699867
[TBL] [Abstract][Full Text] [Related]
5. Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis.
Speight RA; Nicolle A; Needham SJ; Verrill MW; Bryon J; Panter S
J Clin Oncol; 2013 Jun; 31(16):e245-7. PubMed ID: 23610110
[No Abstract] [Full Text] [Related]
6. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Shah NP; Lee FY; Luo R; Jiang Y; Donker M; Akin C
Blood; 2006 Jul; 108(1):286-91. PubMed ID: 16434489
[TBL] [Abstract][Full Text] [Related]
7. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Fernández A; Sanguino A; Peng Z; Ozturk E; Chen J; Crespo A; Wulf S; Shavrin A; Qin C; Ma J; Trent J; Lin Y; Han HD; Mangala LS; Bankson JA; Gelovani J; Samarel A; Bornmann W; Sood AK; Lopez-Berestein G
J Clin Invest; 2007 Dec; 117(12):4044-54. PubMed ID: 18060038
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
[TBL] [Abstract][Full Text] [Related]
9. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
[TBL] [Abstract][Full Text] [Related]
10. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
Zheng S; Pan YL; Tao DY; Wang JL; Huang KE
Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980
[TBL] [Abstract][Full Text] [Related]
11. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Bauer S; Duensing A; Demetri GD; Fletcher JA
Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
[TBL] [Abstract][Full Text] [Related]
12. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
[TBL] [Abstract][Full Text] [Related]
13. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
[TBL] [Abstract][Full Text] [Related]
14. Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.
Chen H; Isozaki K; Kinoshita K; Ohashi A; Shinomura Y; Matsuzawa Y; Kitamura Y; Hirota S
Int J Cancer; 2003 May; 105(1):130-5. PubMed ID: 12672043
[TBL] [Abstract][Full Text] [Related]
15. KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.
Tamborini E; Gabanti E; Lagonigro MS; Negri T; Pilotti S; Pierotti MA; Pricl S
Cancer Res; 2005 Feb; 65(3):1115; author reply 1115. PubMed ID: 15705916
[No Abstract] [Full Text] [Related]
16. [Clinical and molecular characterization of gastrointestinal stromal tumors (GIST)].
Mac K; Wójcik M
Postepy Hig Med Dosw (Online); 2007 Jun; 62():272-81. PubMed ID: 18542042
[TBL] [Abstract][Full Text] [Related]
17. Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour.
Grimpen F; Yip D; McArthur G; Waring P; Goldstein D; Loughrey M; Beshay V; Chong G
Lancet Oncol; 2005 Sep; 6(9):724-7. PubMed ID: 16129374
[No Abstract] [Full Text] [Related]
18. Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
Demetri GD
J Clin Invest; 2007 Dec; 117(12):3650-3. PubMed ID: 18060025
[TBL] [Abstract][Full Text] [Related]
19. [Establishment and pathologic analysis of imatinib-resistant gastrointestinal stromal tumor xenografts].
Zheng S; Wang XJ; Jia J; Pan YL; Tao DY; Lu HS; Huang KE
Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):176-80. PubMed ID: 22800481
[TBL] [Abstract][Full Text] [Related]
20. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
